Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 73Carcinoma, Renal Cell 36Urinary Bladder Neoplasms 25Carcinoma, Transitional Cell 14Neoplasm Metastasis 12Melanoma 12Ovarian Neoplasms 11Lung Neoplasms 11Colorectal Neoplasms 11Clear-cell metastatic renal cell carcinoma 10Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Wilms Tumor 8Ureteral Neoplasms 8Pancreatic Neoplasms 8Carcinoma, Hepatocellular 8Lymphoma, Non-Hodgkin 7Glioma 7Urethral Neoplasms 6Sarcoma 6Neuroblastoma 6Hepatoblastoma 6Uterine Cervical Neoplasms 5Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Ependymoma 5Central Nervous System Neoplasms 5

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Specimen Handling × Genitourinary × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡